全关节置换术后抗凝药物安全性评估  

Evaluation of the safety of coagulants for prevention of deep vein thrombosis after total joint replacement

作　　者：薛峰[1] 付勤[1] 许晓军[1] 

机构地区：[1]中国医科大学附属盛京医院骨外科,沈阳110004

出　　处：《实用药物与临床》2013年第5期435-437,共3页Practical Pharmacy and Clinical Remedies

摘　　要：目的比较丹参素和盐酸川芎嗪、利伐沙班(拜瑞妥)、低分子肝素钙(速碧林)3种抗凝药物的安全性,为临床选择药物预防深静脉血栓(DVT)提供依据。方法 60例全关节置换患者,按抗凝药物种类进行分组,观察组分别为丹参素和盐酸川芎嗪组17例(膝2例,髋15例),利伐沙班组11例(膝4例,髋7例),低分子肝素钙组15例(膝2例,髋13例);对照组为同期住院未应用抗凝药物共17例(膝5例,髋12例),对各组出血指标(血红蛋白差值、出血发生率、失血指数)进行比较。结果三个观察组与对照组的安全性指标比较差异无统计学意义。各组间出血事件发生率、失血指数、修正输血指数比较差异均无统计学意义(P>0.05)。结论三种抗凝药物均安全有效,且安全性相似。但由于该研究的样本量较小,有可能导致组间差异不显著,而影响安全性的评价。Objective To evaluate the safety of salivae miltiorrhizae liguspyragine hydrochloride and glucose, fraxiparine, xarelto so as to provide evidence for better choice for preventing deep vein thrombosis after total joint re- placement. Methods 60 patients underwent total joint replacement were divided into 4 groups, group S （ n = 17 ） re- ceived Salivae miltiorrhizae liguspyragine hydrochloride and Glucose, group X（ n = 11 ） received Xarelto, group F（ n = 15 ） received FraxiParine ,control group（ n = 17 ）. The bleeding parameter among the groups was compared. Results There was no significant difference in safety among the groups （ P 〉 0. 05 ）. There was no significant difference in Bleeding events incidence, Bleeding index, Revise bleeding index among the groups. Conclusion The three cogulants are similar in the efficacy and safety. But according to the small sample size, the difference may not be so significant.

关 键 词：关节置换术 深静脉血栓 参芎葡萄糖 速碧林 拜瑞妥 

分 类 号：R687.4[医药卫生—骨科学]